{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:02:50Z","timestamp":1781128970330,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clcc.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:22:43Z","timestamp":1771460563000},"page":"271-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable\/Mismatch Repair-Proficient Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Andrea","family":"Bocobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Whitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget P.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin L.","family":"Koser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley A.","family":"Kidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorbarikor","family":"Piawah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Van Loon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer C.","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Pallav","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjusha","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Babdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-1727","authenticated-orcid":false,"given":"Chloe E.","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clcc.2026.02.003_bib0001","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"18_suppl","key":"10.1016\/j.clcc.2026.02.003_bib0002","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/jco.2014.32.18_suppl.lba3","volume":"32","author":"Venook","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.clcc.2026.02.003_bib0003","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.02.003_bib0004","doi-asserted-by":"crossref","unstructured":"Oh DY, Venook AP, Fong L On the verge: immunotherapy for colorectal carcinoma. 2015 Accessed: July 28, 2025 Available at: https:\/\/jnccn.org\/view\/journals\/jnccn\/13\/8\/article-p970.xml.","DOI":"10.6004\/jnccn.2015.0117"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2026.02.003_bib0005","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2016.34.15_suppl.3502","article-title":"Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)","volume":"34","author":"Bendell","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2026.02.003_bib0006","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.19.02394","article-title":"Phase Ib\/ii clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003","volume":"38","author":"Dudek","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.003_bib0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.02.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2010","article-title":"Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM)","author":"Reardon","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"10.1016\/j.clcc.2026.02.003_bib0009","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/jco.2015.33.7_suppl.410","article-title":"Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"33","author":"Sznol","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00262-008-0524-3","article-title":"Anti-angiogenesis: making the tumor vulnerable to the immune system","volume":"57","author":"Griffioen","year":"2008","journal-title":"Cancer Immunol Immunother CII"},{"issue":"4","key":"10.1016\/j.clcc.2026.02.003_bib0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/14712598.7.4.449","article-title":"Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy","volume":"7","author":"Johnson","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.clcc.2026.02.003_bib0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","article-title":"VEGF as a mediator of tumor-associated immunodeficiency","volume":"23","author":"Ohm","year":"2001","journal-title":"Immunol Res"},{"issue":"10","key":"10.1016\/j.clcc.2026.02.003_bib0013","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.clcc.2026.02.003_bib0014","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clcc.2026.02.003_bib0015","series-title":"Cancer Immunology and Immunotherapy","first-page":"129","article-title":"Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin","author":"Kandalaft","year":"2011"},{"issue":"6","key":"10.1016\/j.clcc.2026.02.003_bib0016","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.humimm.2009.01.014","article-title":"Secretion of VEGF by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions","volume":"70","author":"Mulligan","year":"2009","journal-title":"Hum Immunol"},{"issue":"12","key":"10.1016\/j.clcc.2026.02.003_bib0017","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clcc.2026.02.003_bib0018","first-page":"1224","article-title":"Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells","volume":"160","author":"Oyama","year":"1998","journal-title":"J Immunol Baltim Md"},{"issue":"4_suppl","key":"10.1016\/j.clcc.2026.02.003_bib0019","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1200\/JCO.2017.35.4_suppl.673","article-title":"Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)","volume":"35","author":"Hochster","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.02.003_bib0020","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clcc.2026.02.003_bib0021","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.clcc.2026.02.003_bib0022","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-14-0657","article-title":"Adverse immunoregulatory effects of 5FU and cpt11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes","volume":"74","author":"Kanterman","year":"2014","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clcc.2026.02.003_bib0023","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell\u2013dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.clcc.2026.02.003_bib0024","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1245\/s10434-011-1609-3","article-title":"Association of intra-tumoral infiltrating macrophages and regulatory T Cells is an independent prognostic factor in gastric cancer after radical resection","volume":"18","author":"Wang","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.003_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br J Cancer"},{"issue":"14_Supplement","key":"10.1016\/j.clcc.2026.02.003_bib0026","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1538-7445.AM2016-543","article-title":"Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab","volume":"76","author":"Pinheiro","year":"2016","journal-title":"Cancer Res"},{"issue":"10391","key":"10.1016\/j.clcc.2026.02.003_bib0027","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clcc.2026.02.003_bib0028","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (folfox4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clcc.2026.02.003_bib0029","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2005.05.1573","article-title":"Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.02.003_bib0030","unstructured":"Gayoso A, Shor J JonathanShor\/DoubletDetection: doubletdetection v3.0 Zenodo; 2020 Accessed: August 4, 2025 Available from: https:\/\/zenodo.org\/records\/4359992."},{"issue":"1","key":"10.1016\/j.clcc.2026.02.003_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"key":"10.1016\/j.clcc.2026.02.003_sbref0032","series-title":"A phase II trial of neoadjuvant chemoradiation (Crt) and pembrolizumab in patients with rectal cancer","author":"Rahma","year":"2017"},{"key":"10.1016\/j.clcc.2026.02.003_sbref0033","series-title":"A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients","year":"2025"},{"key":"10.1016\/j.clcc.2026.02.003_bib0034","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps4135","article-title":"Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma","volume":"33","author":"Fuchs","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.02.003_bib0035","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.02.003_bib0036","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.003_bib0037","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.clcc.2026.02.003_bib0038","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2026.02.003_bib0039","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.003_bib0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clcc.2026.02.003_bib0041","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","article-title":"Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clcc.2026.02.003_bib0042","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2026.02.003_bib0043","doi-asserted-by":"crossref","first-page":"e1188","DOI":"10.1634\/theoncologist.2020-0161","article-title":"Regorafenib and nivolumab or pembrolizumab combination and circulating tumor dna response assessment in refractory microsatellite stable colorectal cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"issue":"7693","key":"10.1016\/j.clcc.2026.02.003_bib0044","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.clcc.2026.02.003_bib0045","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.23.02736","article-title":"Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study","volume":"42","author":"Kawazoe","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10517","key":"10.1016\/j.clcc.2026.02.003_bib0046","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","volume":"406","author":"Hecht","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clcc.2026.02.003_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.clcc.2026.02.003_bib0048","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2026.02.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9\u00d78 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.003_bib0050","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1186\/s12885-020-07268-4","article-title":"Phase II study on first-line treatment of NIVolumab in combination with folfoxiri\/bevacizumab in patients with advanced COloRectal cancer RAS or BRAF mutated \u2013 NIVACOR trial (GOIRC-03-2018)","volume":"20","author":"Damato","year":"2020","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.clcc.2026.02.003_bib0051","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clcc.2026.02.003_bib0052","first-page":"118","article-title":"Pembrolizumab plus mFOLFOX7 or FOLFIRI for microsatellite stable\/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 Cohorts B and D","volume":"23","author":"Kim","year":"2024","journal-title":"Clin Colorectal Cancer"},{"issue":"5795","key":"10.1016\/j.clcc.2026.02.003_bib0053","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.clcc.2026.02.003_bib0054","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1200\/JCO.23.01648","article-title":"Prognostic and predictive value of immunoscore in stage III colorectal cancer: pooled analysis of cases from the SCOT and IDEA-HORG studies","volume":"42","author":"Domingo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clcc.2026.02.003_bib0055","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.02.003_bib0056","doi-asserted-by":"crossref","unstructured":"Antoniotti C, Carullo M, Rossini D, et al. Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. ESMO Open. 2025 Accessed: January 24, 2026;10(2). Available at: https:\/\/www.esmoopen.com\/article\/S2059-7029(25)00003-1\/fulltext.","DOI":"10.1016\/j.esmoop.2025.104135"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T21:52:30Z","timestamp":1781128350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1533002826000101"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.02.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable\/Mismatch Repair-Proficient Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}